Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

0.5700 -0.0090 (-1.55%)
Official Closing Price Updated: 8:00 PM EDT, Jul 6, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 297,527
Open 0.5849
Bid (Size) 0.5880 (3)
Ask (Size) 0.5899 (1)
Prev. Close 0.5790
Today's Range 0.5600 - 0.5899
52wk Range 0.3903 - 3.220
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Psychedelic Stock Gainers And Losers From July 6, 2022
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 20.50% at $0.89 
Via Benzinga
Archaeologists Believe Hidden Andean Passageways Were Most Likely Used During Psychedelic Rituals
Via Investor Brand Network

Performance

YTD
-53.28%
-53.28%
1 Month
-25.97%
-25.97%
3 Month
-30.49%
-30.49%
6 Month
-49.56%
-49.56%
1 Year
-79.35%
-79.35%

More News

Read More
Numinus Wellness, Mind Medicine Among Top Psychedelic Movers Of Today
Via Benzinga
New Study Finds That Probiotics May Be Useful in Fight Against Depression
Via Investor Brand Network
Psychedelic Stock Gainers And Losers From July 1, 2022
Via Benzinga
June Update: Psychedelic Compounds-Based Drug Stocks Index Up 8%; Down 55% YTD
Via Talk Markets
Psychedelic Stock Gainers And Losers From June 30, 2022
Via Benzinga
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
Via Benzinga
NJ Senate President Introduces Psilocybin Legalization Bill Containing Home-Cultivation Provision
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Via Investor Brand Network
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
Via Benzinga
Cybin Announces Additional Adelia Milestone Achievement
From Cybin Inc.
Via Business Wire
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
Rebalanced Psychedelic Compounds-Based Drug Stocks Index Down 52.7% YTD
Via Talk Markets
Why More Attention Needs to Be Paid to Paternal Mental Health
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
Via Investor Brand Network
Exposures Product Safety
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
From Cybin Inc.
Via Business Wire
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
Via Benzinga
New Netflix Series to Explore the Use of Psychedelics for Mental Health
Via Investor Brand Network
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
Via Benzinga
Psychedelic Stock Gainers And Losers From June 22, 2022
Via Benzinga
Cybin Closes Fiscal Year 2022, Reports Financial Results And Major Achievements
Via Benzinga
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Business Highlights, FY 2022 Results
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.